Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for TransCode Therapeutics Inc. (RNAZ : NSDQ)
 
 • Company Description   
TransCode Therapeutics is an emerging RNA oncology company. Its platform of investigational drug candidates is dedicated to improving patient outcomes encompassing a variety of tumor types. The company's lead therapeutic candidate includes TTX-MC138. TransCode Therapeutics is based in BOSTON.

Number of Employees: 7

 
 • Price / Volume Information   
Yesterday's Closing Price: $9.00 Daily Weekly Monthly
20 Day Moving Average: 24,949 shares
Shares Outstanding: 0.83 (millions)
Market Capitalization: $7.50 (millions)
Beta: 1.40
52 Week High: $905.52
52 Week Low: $6.15
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 24.91% 20.24%
12 Week 17.91% -0.82%
Year To Date -90.47% -91.07%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
6 Liberty Square #2382
-
Boston,MA 02109
USA
ph: 857-837-3099
fax: -
alan.freidman@transcodetherapeutics.com http://www.transcodetherapeutics.com
 
 • General Corporate Information   
Officers
Thomas A. Fitzgerald - Interim Chief Executive Officer and Chief Financia
Philippe P. Calais - Chairman
Erik Manting - Director
Magda Marquet - Director
Magda Marquet - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 89357L501
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/13/25
Share - Related Items
Shares Outstanding: 0.83
Most Recent Split Date: 5.00 (0.04:1)
Beta: 1.40
Market Capitalization: $7.50 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/13/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.73
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 97.20%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -578.88
12/31/24 - -1,209.97
ROA
06/30/25 - -
03/31/25 - -222.61
12/31/24 - -287.08
Current Ratio
06/30/25 - -
03/31/25 - 5.20
12/31/24 - 2.56
Quick Ratio
06/30/25 - -
03/31/25 - 5.20
12/31/24 - 2.56
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - 12.35
12/31/24 - -54.96
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - -
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - -
 

Powered by Zacks Investment Research ©